[Iscador QuS and human recombinant interferon alpha (Intron A) in cervical intraepithelial neoplasia (CIN)].
For several years there has been the association between the persistent HPV infection (especially with high oncogenic potency i.e. 16, 18) and the cervical intraepithelial neoplasia. The pathomechanism is probably considered with spread of the early virus gene E1, E2 and the suppressor protein p53 complexes. Further on these complexes cause the neoplastic cell transformation. There has also been described the role of impaired immune response in these cases. The abnormalities cover malformation of antigen presenting system APC, decrease of MHC-I and MHC-II heavy chains rate, decrease of the Langer-hans cells and decrease of count and cytotoxic activities of lymphocytes B and NK cells. The invasive and destructive techniques of HPV associated CIN treatment do not respect its pathogenesis. Therefore the new non surgical methods of treatment would play a major role in treatment and prevention of women especially in their reproductive period. The aim of this work was the evaluation of the Iscador QuS and Intron A role in the management of HPV associated CIN. The 60 patients with CIN and HPV have been diagnosed and treated in our clinic for 12 months. Early results present increase of regression and significant decrease of progression rates in both groups of examined women, comparing to the control group. The stationery state rates in this groups of women were similar to the control group.
Jach
R
R
Katedry i Kliniki Ginekologii i Onkologii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie.
Basta
A
A
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D030361:Papillomavirus Infections / Q000150:complications / Q000188:drug therapy; D010936:Plant Extracts / Q000627:therapeutic use*; D010940:Plant Proteins; D011994:Recombinant Proteins; D014412:Tumor Virus Infections / Q000150:complications / Q000188:drug therapy; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000276:immunology; D002578:Uterine Cervical Dysplasia / Q000188:drug therapy* / Q000276:immunology
D000972:Antineoplastic Agents, Phytogenic; D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D010936:Plant Extracts; D010940:Plant Proteins; D011994:Recombinant Proteins; C077177:viscum album peptide
Iscador QuS i ludzki rekombinowany interferon alfa (Intron A) w śródnabłonkowej neoplazji szyjki macicy (CIN).